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Melanina b s t r a c t
Sonodynamic therapy (SDT) involves the activation of a non-toxic sensitiser drug using low-intensity
ultrasound to produce cytotoxic reactive oxygen species (ROS). Given the low tissue attenuation of ultra-
sound, SDT provides a significant benefit over the more established photodynamic therapy (PDT) as it
enables activation of sensitisers at a greater depth within human tissue. In this manuscript, we compare
the efficacy of aminolevulinic acid (ALA) mediated PDT and SDT in a squamous cell carcinoma (A431) cell
line as well as the ability of these treatments to reduce the size of A431 ectopic tumours in mice.
Similarly, the relative cytotoxic ability of Rose Bengal mediated PDT and SDT was investigated in a
B16-melanoma cell line and also in a B16 ectopic tumour model. The results reveal no statistically signif-
icant difference in efficacy between ALA mediated PDT or SDT in the non-melanoma model while Rose
Bengal mediated SDT was significantly more efficacious than PDT in the melanoma model. This difference
in efficacy was, at least in part, attributed to the dark pigmentation of the melanoma cells that effectively
filtered the excitation light preventing it from activating the sensitiser while the use of ultrasound cir-
cumvented this problem. These results suggest SDT may provide a better outcome than PDT when treat-
ing highly pigmented cancerous skin lesions.
 2016 Published by Elsevier Ltd.1. Introduction
Photodynamic therapy (PDT) is currently approved as a first line
treatment for non-melanoma skin cancer and has been trialled in
the treatment of other cancers such as head and neck, oesophageal,
bladder and prostate.1,2 PDT requires the presence of three distinct
components before a cytotoxic effect can be observed; (i) a sensi-
tising drug, (ii) light of an appropriate wavelength and (iii) molec-
ular oxygen. The combination of all three components result in the
generation of singlet oxygen and other reactive oxygen species
(ROS), that when generated in sufficient quantities, result in cell
death.3 The attraction of PDT over other cancer therapies is that
generation of the cytotoxic species can be controlled by careful
positioning of the illumination source. This targeting is further
enhanced when treating skin cancer as the sensitiser prodrug
aminolevulinic acid (ALA) is converted to the active sensitiser pro-
toporphyrin IX (PpIX) more effectively by cancer cells when com-pared to non-cancer cells. PpIX is naturally generated during the
cellular heme cycle and is meticulously controlled to prevent its
natural accumulation.4 This negative feedback system is thought
to be modified in cancer tissues due to enzymatic defects that lead
to an increase in protoporphyrinogen IX oxidase and/or reduced
activity of ferrochelatase.5 Another advantage of PDT is the excel-
lent cosmetic outcome observed post treatment when compared
to surgery or topical chemotherapy treatment (i.e., 5-fluo-
rouracil).6,7 However, the limited penetration of light through
mammalian tissue has restricted the use of PDT to the treatment
of superficial lesions and reduces its effectiveness in treating more
deeply-seated or highly pigmented lesions.8 Indeed, while PDT is
routinely used to treat superficial basal cell carcinoma (BCC), it is
not indicated for the treatment of malignant melanoma.9 The dark
pigmentation associated with melanotic lesions acts as a filter for
the light used to activate the majority of conventional sensitizers
that absorb in the visible range of the electromagnetic spectrum.10
To compound matters further, melanin has natural anti-oxidant
properties thereby acting as a scavenger for ROS generated during
PDT.11,12 The development of near-infrared (NIR) absorbing sensi-
tizers that possess absorption maxima in a region where melanin
2 C. McEwan et al. / Bioorg. Med. Chem. xxx (2016) xxx–xxxdoes not absorb have produced impressive results in treating mel-
anoma, suggesting the anti-oxidant effect of melanin may be over-
come when using PDT.13–16
Sonodynamic therapy (SDT) has recently emerged as an alterna-
tive to PDT and uses low intensity ultrasound instead of light to
activate the sensitiser. This interaction of the sensitiser with an
acoustic field generates ROS that result in cytotoxic effects similar
to those observed in PDT.17,18 The major benefit of using SDT
instead of PDT is that ultrasound is clinically approved as a safe
and effective imaging modality and unlike light can achieve pene-
tration depths in soft tissue in the region of tens of centimetres.19
Therefore, SDT offers the potential of treating more deeply seated
solid tumours than currently possible using PDT.
In this manuscript, we compare the effectiveness of PDT and
SDT at treating non-melanoma and melanoma skin cancer in pre-
clinical models. Specifically, we determine the effect of ALA medi-
ated PDT/SDT in treating A431 squamous cell carcinoma and Rose
Bengal mediated PDT/SDT in treating B16-F10-Luc2 melanoma
cells both in vitro and in vivo. The resulting efficacy of these treat-
ments is then discussed.
2. Experimental
2.1. Materials and reagents
ALA and Rose Bengal were purchased from Aldrich at the high-
est grade possible. Metvix cream was purchased from Galderma.
All other chemicals were purchased from commercial sources at
the highest possible purity and used as received. Human epider-
moid carcinoma A431 cell line was obtained from ATCC and the
B16-F10-Luc2 cell line was purchased from PerkinElmer. SCID
and athymic nude mice were obtained from Harlan Laboratories.
In these studies all animals were treated humanely and in accor-
dance with licensed procedures under the UK Animals (Scientific
Procedures) Act 1986.
2.2. ALA mediated PDT and SDT treatment of A431 cells in vitro
A431 cells, maintained in DMEM medium supplemented with
10% (v/v) foetal bovine serum at 37 C in a humidified 5% (v/v)
CO2 atmosphere were seeded into wells of a 96-well tissue culture
plate at a concentration of 5  103 cells per well and incubated
overnight. The medium was then removed and replaced with
100 lL of ALA solution in PBS at concentrations of 1 or 2 lM. The
cells were then incubated for a further 4 h at 37 C in a humidified
5% (v/v) CO2 atmosphere, the ALA solution removed, the wells
washed with PBS and treated with either red light using a Pho-
totherapeutics Paterson BL1000A lamp (630 nm ± 15 nm, total
dose = 5 J/cm2) or ultrasound (Sonidel SP 100 sonoporator, fre-
quency = 1 MHz, a power density = 3.0 W cm2, 50% duty cycle
(pulse repetition frequency = 100 Hz, total dose = 90 J/cm2) from
the underside of the plate. The wells were washed with PBS and
100 lL aliquots of DMEM medium supplemented with 10% (v/v)
foetal bovine serumwere dispensed into each well. The plates were
then incubated in a humidified 5% CO2 atmosphere at 37 C for 21 h
and cell viability then determined using an MTT assay.20 A similar
procedure was repeated using ALA at the same concentrations
without stimulus. Results were compared against control experi-
ments where cells were treated with only the vehicle (i.e., PBS).
2.3. DPBF assay of PpIX and Rose Bengal
An EtOH/H2O (50:50 v/v) (10 mL) solution was prepared con-
taining PpIX or Rose Bengal (0.5 lM) and 1,3-diphenylisobenzofu-
ran (DPBF) (20 lM). The solutions were then irradiated for 30 minPlease cite this article in press as: McEwan, C.; et al. Bioorg. Med. Chemwith white light (Fenix LD01 LED, 50 mW output) or ultrasound
(Sonidel SP 100 sonoporator, frequency = 1 MHz, a power den-
sity = 3.0 W cm2, 50% duty cycle, pulse repetition fre-
quency = 100 Hz). Aliquots were taken at specific time points and
the absorbance at 410 nm recorded using a Cary 50 UV–Vis spec-
trometer. Control experiments in the absence of drug (i.e., DPBF
+ stimulus) were also performed for comparative purposes.
2.4. PDT and SDT treatment of human xenograft A431 tumours
in SCID mice using topical Metvix cream
A431 cells were maintained in DMEM medium supplemented
with 10% foetal bovine serum. Cells were cultured at 37 C in a
humidified 5% (v/v) CO2 atmosphere. The cells (1  106) were re-
suspended in 100 lL of Matrigel and implanted into the rear dor-
sum of female SCID mice. Tumour formation occurred approxi-
mately 2 weeks after implantation and tumour measurements
were taken daily using calipers. Once the tumours had reached
an average volume of 205 mm3, calculated from the geometric
mean diameter using the equation, tumour volume = 4pR3/3, ani-
mals were randomly distributed into 3 groups (n = 3) which
included (i) no stimulus group (control), (ii) a PDT treated group
and (iii) a SDT treated group. Following induction of anaesthesia
(intraperitoneal injection of Hypnorm/Hypnovel), a 1 mm thick
layer of Metvix cream was topically applied to the tumour and
5–10 mm of the surrounding skin.21 The residual cream was then
removed 4 h later, and the tumours treated with (i) no stimulus
(ii) red-light (total dose: 40 J/cm2) or ultrasound (at a frequency
of 1 MHz using 3.5 W/cm2 and a duty cycle of 30% – total dose:
220 J/cm2). After treatment, animals were allowed to recover
from anaesthesia and tumour volume and body weight were
recorded on a daily basis for 7 days.
2.5. PDT and SDT treatment of RIF-1, HeLa and B16 melanoma
cells using Rose Bengal
B16-F10-Luc2 melanoma and HeLa cells were cultured in Dul-
becco’s Modified Eagle Medium (DMEM) supplemented with 10%
(v/v) Foetal Bovine Serum (FBS) while RIF-1 cells were cultured
in Roswell Park Memorial Institute-1640 medium (RPMI-1640)
supplemented with 10% (v/v) FBS. All cell lines were incubated at
37 C in a humidified 5% (v/v) CO2 atmosphere. Cells were seeded
at a concentration of 5  103 cells per well in 96-well tissue culture
plate for 24 h. The medium was then removed from each well and
replaced with 100 lL of Rose Bengal at a concentration of 0.5 lM.
The cells were incubated for 3 h at 37 C in a humidified 5% (v/v)
CO2 atmosphere. Individual wells were washed with PBS to remove
excess Rose Bengal before treatment with either white light
(parameters as in Section 2.3: 30 s, total dose: 11.4 J/cm2 or
60 s, total dose 22.8 J/cm2) or ultrasound (parameters as in Sec-
tion 2.2, 30 s, total dose: 45 J/cm2 or 60 s, total dose: 90 J/cm2)
for 30 or 60 s. Wells were washed again with PBS and 100 lL ali-
quots of the respective medium supplemented with 10% (v/v) foe-
tal bovine serum were dispensed into each well. Plates were then
incubated in a humidified 5% CO2 atmosphere at 37 C for 21 h.
The cell viability was then determined using a MTT assay. A similar
procedure was repeated using RB at the same concentration in the
absence of light or ultrasound and for stimulus alone. Results were
compared against control experiments where cells were treated
with only the vehicle (i.e., PBS).
2.6. PDT and SDT treatment of ectopic B16 melanoma tumours
in nude mice using Rose Bengal
B16-F10-Luc2 cells (3  105) maintained as described in Sec-
tion 2.4, were re-suspended in 100 lL of PBS and implanted into. (2016), http://dx.doi.org/10.1016/j.bmc.2016.05.015
C. McEwan et al. / Bioorg. Med. Chem. xxx (2016) xxx–xxx 3the rear dorsum of male nude mice. Tumour formation occurred
approximately 10 days after implantation and tumour measure-
ments were taken every other day using calipers. Once the
tumours had reached an average volume of 246 mm3, calculated
from the geometric mean diameter using the equation: tumour
volume = 4pR3/3, animals were randomly distributed into two
treatment groups, PDT and SDT (n = 3). Following induction of
anaesthesia (intraperitoneal injection of Hypnorm/Hypnovel), a
100 lL aliquot of PBS containing 100 lM RB was injected directly
into each tumour and animals were treated with either with white
light (parameters as in Section 2.4; total dose: 68.4 J/cm2) or
ultrasound (parameters as in Section 2.4, total dose: 220 J/cm2).
After treatment animals were allowed to recover from anaesthesia
and tumour volume was monitored up to 6 days after the proce-
dure. Where applicable, treatment was also repeated on days 2
and 4 after the daily measurement was taken. The % increase in
tumour volume was calculated employing the pre-treatment mea-
surements for each group.
2.7. In vitro PDT/SDT treatment through a skin barrier
The procedure outlined in Section 2.4 was repeated using RIF-1
cells with the following modification: after incubation with Rose
Bengal for 3 h, individual wells were washed with PBS to remove
excess RB and sections of guinea pig skin ranging from 1.7, 3.4,
5.1 or 6.4 mm thick, prepared by repeatedly doubling the skin over,
were fixed to the underside of the wells before being treated with
either white light or ultrasound. Following determination of cell
viability using a MTT assay the results were compared against
the cytotoxicity observed when no skin barrier was applied
between the stimulus and the plate.
3. Results & discussion
The initial focus of this study was to evaluate the efficacy of ALA
mediated SDT as a treatment for non-melanoma skin cancer when
compared to conventional ALA mediated PDT treatment. To enable
this comparison, A431 squamous cell carcinoma cells were seeded
in a 96 well plate and incubated with ALA (1 or 2 lM) for 4 h fol-
lowed by treatment with either red light (630 nm ± 15 nm) or
ultrasound. The cell viability was determined 24 h later using a
MTT assay. The results (Fig. 1a) show that both PDT and SDT treat-
ments produced statistically significant reductions in cell viability
at each ALA concentration tested compared to the ALA only control
(i.e., no stimulus). Indeed, at the higher concentration of ALA
(2 lM), reductions in cell viability of 31% (p <0.01) and 43%

























Figure 1. (a) Plot showing % viability for A431 cells treated with ALA (1 or 2 lM) and
compared to ALA alone at the appropriate concentration. Error bars represent SEM wh
concentration. (b) Plot of relative absorbance at 410 nm for solutions of DPBF treated wi
light (filled circles); (iv) PPIX and ultrasound (open circles); (v) Rose Bengal and lig
represent ± SEM where n = 3.
Please cite this article in press as: McEwan, C.; et al. Bioorg. Med. Chemmore, neither stimulus alone (i.e., light or ultrasound) caused any
negative effect on cell viability. These results suggest that after
conversion of ALA to the active sensitiser PpIX by the cellular heme
pathway, application of light or ultrasound generates ROS resulting
in the observed cytotoxic effect.
The improvement in efficacy observed for PDT compared to SDT
in these experiments most likely results from PpIX being a more
efficient photosensitiser than sonosensitiser. To determine if this
was the case, we utilised the chromogenic ROS probe 1,3-
diphenylisobenzofuran (DPBF). DPBF displays a strong absorbance
band at 410 nm in its native furan form but is bleached to the cor-
responding diketone upon interaction with ROS. By measuring the
reduction in the absorbance of the furan form at 410 nm an indica-
tion of ROS production is possible.19 We treated solutions contain-
ing PpIX and DPBF with light or ultrasound and measured the
amount of ROS generated in each case. Figure 1b shows a plot of
% reduction in DPBF absorbance against time following irradiation
with light or ultrasound and confirms PpIX to be a much more effi-
cient photosensitiser than a sonosensitiser. Indeed, after 30 min
irradiation with light, a 60% reduction in DPBF absorbance (relative
to light only control) was observed while the corresponding reduc-
tion for ultrasound (relative to ultrasound only control) was only
17%. This variation in ROS production by PPIX and Rose Bengal is
in keeping with their singlet oxygen quantum yields with Rose
Bengal being a much better singlet oxygen generator upon light
irradiation than porphyrins (Refs.22,23). While the mechanism for
ROS production in PDT is well understood, the mechanism for
the generation of ROS in SDT is less clear. One suggestion is that
the process of ultrasound inertial cavitation, which involves the
formation, oscillation and collapse of gas filled bubbles in samples
irradiated with ultrasound is responsible for initiating the genera-
tion of ROS in SDT.19 When this cavitation phenomenon becomes
dominated by inertial forces, the bubbles collapse violently leading
to sonoluminescence emission.19 This luminescence emission may
subsequently excite the nearby sonosensitiser by an energy trans-
fer process resulting in the generation of ROS by the very same
mechanism as in PDT. Another possible explanation is that
sonosensitiser drugs in the vicinity of collapsing bubbles experi-
ence such high local temperatures that ROS are generated through
pyrolysis reactions. The results shown in Figure 1b reveal a similar
pattern in the amount of ROS generated for PPIX and Rose Bengal
when irradiated with light and ultrasound suggesting a sonolumi-
nescence mechanism may be involved.
Having determined the effect of PDT and SDT treatment on
A431 cells in vitro, the next step was to evaluate the effect of these
treatments in vivo. Ectopic A431 tumours were established on the























light or ultrasound. **p <0.01, ***p <0.001 for ultrasound or light treatment of ALA
ere n = 4. Dp <0.05 for light versus ultrasound treatment of ALA at the appropriate
th (i) ultrasound only (open triangles); (ii) light only (filled triangles); (iii) PpIX and
ht (open squares) and (vi) Rose Bengal + ultrasound (filled squares). Error bars
. (2016), http://dx.doi.org/10.1016/j.bmc.2016.05.015
4 C. McEwan et al. / Bioorg. Med. Chem. xxx (2016) xxx–xxxvolume of 205 mm3, topical methyl aminolevulinate was adminis-
tered to each tumour in the form of Metvix cream. Four hours later,
residual cream was removed and the animals were separated into
three groups. One group was exposed to red light
(630 nm ± 15 nm), one group to ultrasound and one group received
no stimulus. The tumour volume was recorded each day for a per-
iod of one week. The results are shown in Figure 2a and reveal an
almost identical growth profile for animals treated using PDT or
SDT, with tumours being 22% and 11% greater respectively at day
7 when compared to their pre-treatment volume. In contrast,
tumours in the Metvix only group grew by 90% over the same time
period. Indeed, while PDT proved more effective in the 2D cell cul-
ture experiments mentioned above, no statistically significant dif-
ference was observed between PDT or SDT treatment in vivo. This
suggests that while PpIX is a more potent photosensitiser than it is
a sonosensitiser, the ability to activate it at a greater depth using
ultrasound in a 3D tumour environment, compensates for its
reduced ROS production when compared to light activation, result-
ing in a similar if not slightly better tumour reduction effect for
SDT compared to PDT, particularly at the later time points. Analysis
of the average body weight for animals in each of the groups
showed no noticeable reductions over the course of the experiment
suggesting either PDT or SDT treatment did not produce any acute
adverse effects (Fig. 2b).
The second part of this study investigated the relative efficacy
of PDT and SDT for the treatment of melanoma skin cancer. Lucifer-
ase expressing B16 melanoma cells were selected as a target as
these cells form extremely aggressive highly pigmented tumours.24
We were interested in determining if the pigmentation present in
these cells would inhibit PDT treatment and if SDT could provide
any benefit given the ability of low intensity ultrasound to pene-
trate deep into mammalian tissue regardless of its pigmentation.
To test this hypothesis, we first evaluated the efficacy of Rose Ben-
gal mediated PDT or SDT treatment on two amelanotic cancerous
cell lines (HeLa & RIF-1) as well as the melanin producing B16 cells.
Rose Bengal was chosen as a sensitiser in these experiments due to
its superior singlet oxygen quantum yield when compared to
PpIX.22,23 In addition, Rose Bengal is also a more potent sonosensi-
tiser than PpIX as evidenced by the DPBF assay results shown in
Figure 1b. The three cell lines were incubated with Rose Bengal
for 3 h at a concentration of 0.5 lM and exposed to either white
light or ultrasound for treatment periods of 30 or 60 s. The cell via-
bility was measured 24 h later using a MTT assay and the results
are shown in Figure 3.
Both PDT and SDT treatment of the RIF-1 and HeLa cells pro-
duced similar reductions in cell viability (50%) which was statis-
tically significant relative to the untreated control (p <0.001).
However, in the B16 melanoma cells, SDT provided a significantly
improved reduction in viability compared to PDT for both the 30Figure 2. (a) Plot of % tumour growth against time for ectopic A431 tumours treated w
+ ultrasound (open squares). Error bars represent SEM where n = 3. *p <0.05, (ii) compare
(i)–(iii) over the course of the experiment.
Please cite this article in press as: McEwan, C.; et al. Bioorg. Med. Chemand 60 s irradiation times. Specifically, 30 s SDT treatment resulted
in a 25% reduction in cell viability while the same duration of PDT
treatment produced a mere 7% reduction. Similarly, 60 s SDT treat-
ment reduced viability by 40% while for PDT a reduction of only
18% was observed. This statistically significant improvement in
efficacy (p <0.001) for SDT when compared to PDT is more clearly
observed in the line graph of cell viability against irradiation time
(Fig. 3d) where the poor efficacy of PDT in the B16 cells is clearly
differentiated from PDT treatment of the two non-melanotic cell
lines. Furthermore, SDT treatment results in comparable reduc-
tions in cell viability in all three cell lines and is also similar to
the reductions observed for PDT treatment of the two amelanotic
cell lines. These results support the conclusion that the melanin
present in B16 melanoma cells effectively filters the excitation
light destined for the sensitiser thereby inhibiting PDT efficacy
while SDT treatment remains relatively unaffected.
While the above results suggest that the efficacy of SDT is unaf-
fected by tissue pigmentation, these experiments were performed
in a 2D cell culture environment and provide no evidence on the
ability of ultrasound to activate sensitisers at depth within human
tissue. To investigate this, an in vitro model was established where
a guinea-pig skin barrier was inserted between the applied stimu-
lus (i.e., light or ultrasound) and the cells, with the thickness of the
skin barrier (0–6.8 mm) being gradually increased between exper-
iments. The resulting efficacy of PDT and SDT treatments was mea-
sured after each experiment and the results expressed as the %
reduction in cytotoxicity as a function of skin thickness. As can
be observed in Figure 4a, the efficacy of PDT treatment was inhib-
ited significantly more than SDT with increasing skin thickness. For
example, when the skin barrier was 3.4 mm, the cytotoxicity of
PDT treatment reduced by 47% (i.e., compared to no skin barrier)
while cytotoxicity of SDT treatment reduced by only 6%. Similarly,
when the skin barrier was increased to 6.8 mm, PDT efficacy
reduced by 82%, while the SDT efficacy reduced by only 29%. These
results confirm that low intensity ultrasound penetrates mam-
malian tissue much more effectively than white light, and, as a
consequence, is able to activate Rose Bengal more effectively lead-
ing to an improved therapeutic response.
To determine if the in vitro effects observed above would also
be apparent in vivo, ectopic B16 melanoma tumours were estab-
lished in athymic nude mice. These tumours are extremely aggres-
sive and possess a high degree of pigmentation (Fig. 4b). Once the
tumours reached an average volume of 246 mm3 the mice were
separated into two groups, with one group receiving PDT treat-
ment and the second group SDT treatment. This pre-treatment
tumour volume is much higher than typically reported for other
in vivo experiments using this tumour model,15,25,26 and was
selected intentionally to challenge the ability of SDT to produce
cytotoxic effects in such a large and highly pigmented lesion. Theith (i) no treatment (diamonds); (ii) metvix + light (filled squares) and (iii) metvix
d to (i) and (iii) compared to (i). (b) Plot of average body weight for mice in groups
. (2016), http://dx.doi.org/10.1016/j.bmc.2016.05.015
Figure 3. Plot of cell viability for (a) RIF-1, (b) HeLa and (c) B16 melanoma cells treated with 0.5 lM Rose Bengal alone or in combination with light (30 or 60 s) or ultrasound
(30 or 60 s). (d) Line graph combining data from (a) to (c). Error bars represent SEM where n = 4. *p <0.05, **p <0.05, ***p <0.001 for PDT or SDT treatments compared to no
stimulus (i.e., Rose Bengal alone). DDDp <0.001 for SDT treatment, compared to PDT treatment, at the appropriate irradiation time.
Figure 4. (a) Plot showing % reduction in cell viability for RIF-1 cells treated with 0.5 lM Rose Bengal and exposed to either light or ultrasound delivered through guinea-pig
skin of various thickness. (b) Representative image of B16-F10-Luc2 ectopic tumours used in this study. Error bars represent SEM where n = 3.
C. McEwan et al. / Bioorg. Med. Chem. xxx (2016) xxx–xxx 5tumour volume was recorded each day following treatment until
the tumours reached the maximum permissible volume. The
results, shown in Figure 5a, reveal a substantial reduction in
tumour growth for the SDT treated mice compared to the PDT trea-
ted mice (p <0.05). Indeed, four days following treatment, tumours
in the PDT group were approximately 400% larger than their pre-
treatment size while tumours in the SDT group had grown by onlyPlease cite this article in press as: McEwan, C.; et al. Bioorg. Med. Chem120%. Due to the size of the tumours in the PDT group no further
measurements could be taken after day 4 and the animals were
euthanised. However, for the SDT treated animals, tumours were
within the maximum permissible limits for up to six days follow-
ing treatment reaching the same 400% increase in tumour growth
observed for the PDT group at day 4. Again, no noticeable reduction












Figure 5. (a) Plot showing % tumour growth plotted as a function of time for ectopic B16-F10-Luc2 tumours treated with Rose Bengal and light (filled squares) or ultrasound
(open squares). Untreated control group shown as solid squares. (b) Plot of average body weight for mice in the PDT and SDT groups over the course of the experiment. Mice
in the PDT group were euthanised on day 4 as their tumour volume was approaching the maximum permissible value. Error bars represent SEM where n = 3.
6 C. McEwan et al. / Bioorg. Med. Chem. xxx (2016) xxx–xxxover the course of this experiment. These results complement
those from the in vitro studies and highlight the benefit of SDT
when compared to PDT in the treatment of highly pigmented
lesions.
In conclusion, we have demonstrated that ALA mediated PDT
and SDT provide similar therapeutic outcomes using the A431 pre-
clinical human squamous cell carcinoma tumour model in mice. In
addition, when treating a preclinical model for pigmented mela-
noma in vitro and in vivo, SDT was found to be superior to PDT
and the data suggest that this results from the ability of ultrasound
to circumvent light penetration challenges presented by pigmenta-
tion in such lesions. We believe the data presented in this study
suggest that SDT could play a significant role in the treatment of
lesions that are currently beyond the therapeutic capabilities of
PDT.
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